Entities / Place
Als.
river in Vienna
- Reports this week
- 0
- Active events
- 0
- Connections
- 53
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
A fundraising ride associated with the Tomassoni Tour supports ALS research and caregiver costs.Some support1 report
-
Heaven Hill and Elijah Craig bourbon sales proceeds are being used to fund ALS research.Some support1 report
-
SLAM Exploration Ltd. is conducting mineral exploration at the Moose Lake Gold-Antimony Project, receiving and sending core samples for multi-element analysis.Some support2 reports
One to three months ago
-
Research found that the C9ORF72 gene mutation is linked to both ALS and dementia.Some support1 report
-
Inceptua Group and TikoMed AB are collaborating on an investigational drug for progressive neurodegenerative disorders, including ALS.Some support1 report
-
Dale E. Bredesen's theory is being applied to the topic of ALS.Some support2 reports
-
Upwork has higher revenue and earnings than ALS, and both companies are being compared as industrial investment options.Some support2 reports
-
Promis Neurosciences announced preclinical programs targeting TDP-43 in ALS, antibody therapies for early Alzheimer's, and alpha-synuclein.Some support1 report
-
John Pizimolas was appointed CCO at Paragon Advanced Labs Inc., leveraging his background at Bureau Veritas and ALS.Some support1 report
-
Medicare covers people with ALS, referencing the bill establishing Medicare in 1965.Some support2 reports
-
Food City is partnering with Robert Thomas's organization for a campaign supporting veterans with diseases like ALS.Some support1 report
Gone quiet
No new reports in 90+ days-
Klotho Neurosciences received Orphan Drug Designation from the FDA for its KLTO-202 gene therapy, targeting ALS, Alzheimer's, and Parkinson's.Some support4 reports1 development inside
-
Global license agreement accelerates commercialization of NUZ-001 for neurodegenerative diseases.Speculative1 report
-
Amylyx Pharmaceuticals received FDA Fast Track designation on August 7, 2025, for treatments aimed at ALS, including evaluating avexitide post-RYGB surgery.Some support3 reports2 developments inside
-
UniQure is advancing its ALS programs, including AMT-130 targeting Huntington’s disease, with FDA alignment supporting BLA submission.Some support2 reports
-
Athira Pharma is developing ATH-1105, a potential therapy for ALS and other neurodegenerative diseases.Some support1 report
-
Amylyx Pharmaceuticals previously treated ALS using AMX0035 and gained approval in Canada.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Als this week
News at the entities that move Als most-
Medicare StructuralLeaders call for slowing AI development pace, concurrent with an AI model built by OpenAI being hacked via the Medicare portal.Moves Als
-
UniQure (Netherlands) OperationalTrump pledged to unleash American oil and gas and advised investors on market timing in August 2025.Moves Als
-
Kentucky Shared contextSilver Elephant Mining Corp., based in Vancouver and listed on the TSX, has optioned a project in Kentucky.Moves Als
-
Dementia Mentioned togetherA conclave was held in New Delhi, emphasizing that India must prioritize dementia prevention and care.Moves Als
-
China Shared contextThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Als
Connections
The 10 strongest of 53, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Medicare Structural
Medicare provides formal coverage for individuals affected by ALS.
-
UniQure (Netherlands) Operational
UniQure is actively advancing proprietary gene therapies for ALS.
-
Food City Shared context
Food City is mentioned in the context of a campaign supporting veterans in the location Als.
-
Kentucky Shared context
ALS is documented as a medical condition present within the geographical boundaries of Kentucky.
-
Dementia Mentioned together
Dementia and ALS are linked by the shared causal factor of the C9ORF72 mutation.
-
China Shared context
Als is a location whose context is often discussed alongside China in geopolitical analyses.
-
Brainstorm Mentioned together
Brainstorm is developing therapeutics targeting neurodegenerative diseases like ALS.
-
Dale E. Bredesen Shared context
Bredesen's theory is discussed in the context of ALS within the location Als.
Show all 10 connections
-
Amylyx Pharmaceuticals Mentioned together
Amylyx Pharmaceuticals' activities regarding ALS are documented, but no direct relationship with Als is observed in the evidence.
-
James Lyon Mentioned together
The single snapshot describes a personal fact about James Lyon, not a coupling relationship with the location Als.
History
Events by the month they beganSeptember 2026
3 events- A fundraising ride associated with the Tomassoni Tour supports ALS research and caregiver costs.
- Heaven Hill and Elijah Craig bourbon sales proceeds are being used to fund ALS research.
- SLAM Exploration Ltd. is conducting mineral exploration at the Moose Lake Gold-Antimony Project, receiving and sending core samples for multi-element analysis.
August 2026
6 events- Research found that the C9ORF72 gene mutation is linked to both ALS and dementia.
- Inceptua Group and TikoMed AB are collaborating on an investigational drug for progressive neurodegenerative disorders, including ALS.
- Dale E. Bredesen's theory is being applied to the topic of ALS.
- Upwork has higher revenue and earnings than ALS, and both companies are being compared as industrial investment options.
- Promis Neurosciences announced preclinical programs targeting TDP-43 in ALS, antibody therapies for early Alzheimer's, and alpha-synuclein.
- John Pizimolas was appointed CCO at Paragon Advanced Labs Inc., leveraging his background at Bureau Veritas and ALS.
July 2026
1 eventShow 1 earlier month
June 2026
7 events- Medicare covers people with ALS, referencing the bill establishing Medicare in 1965.
- Klotho Neurosciences received Orphan Drug Designation from the FDA for its KLTO-202 gene therapy, targeting ALS, Alzheimer's, and Parkinson's.
- Global license agreement accelerates commercialization of NUZ-001 for neurodegenerative diseases.
- Amylyx Pharmaceuticals received FDA Fast Track designation on August 7, 2025, for treatments aimed at ALS, including evaluating avexitide post-RYGB surgery.
- UniQure is advancing its ALS programs, including AMT-130 targeting Huntington’s disease, with FDA alignment supporting BLA submission.
- Athira Pharma is developing ATH-1105, a potential therapy for ALS and other neurodegenerative diseases.
- Amylyx Pharmaceuticals previously treated ALS using AMX0035 and gained approval in Canada.